Abstract

Drug abuse represents a pervasive global health challenge, with approximately 296 million individuals engaging in illicit drug use and nearly 40 million meeting criteria for substance use disorders. The persistence of drug-seeking behavior despite adverse consequences implicates a complex interplay of neurobiological vulnerabilities, cognitive deficits, socio-affective impairments, and environmental risk factors. This paper presents an integrative framework examining the multifaceted architecture of drug abuse, synthesizing evidence from neurocognitive, social-cognitive, and behavioral economic perspectives. The author reviews converging evidence demonstrating that drug abuse is characterized by heightened impulsivity across attentional, motor, and non-planning domains, with emotion dysregulation mediating the relationship between impulsive traits and dependence severity. Additionally, the author examines deficits in social cognition, including impaired intentional harm recognition and theory of mind processes, particularly among stimulant users, alongside reinforcement pathology wherein drug-related rewards are overvalued while substance-free reinforcers are devalued, creating a constricted behavioral repertoire. The author also considers transdiagnostic mechanisms including interoceptive dysfunction and executive impairment that cut across traditional diagnostic boundaries.
The author proposes that these vulnerabilities operate through a goal-directed regulatory framework wherein individuals with drug abuse histories exhibit inflated discrepancy detection, heightened valuation of drug-related goals, maladaptive strategic preferences toward assimilation, restricted behavioral repertoires, and rigid outcome expectancies. This integrative model suggests that effective intervention must address not only drug use itself but also the underlying socio-affective and cognitive vulnerabilities that maintain addictive behaviors. Clinical implications include the need for socio-emotional regulation training, reinforcement-based interventions promoting alternative reinforcers, and targeted remediation of social-cognitive deficits.

Keywords:Drug abuse; Substance use disorders; Impulsivity; Emotion dysregulation; Social cognition; Reinforcement pathology; Executive function; Transdiagnostic model

Introduction

Drug abuse constitutes one of the most significant public health challenges of the twenty-first century. Global estimates indicate that 296 million people use drugs, representing a 23% increase over the decade from 2011 to 2021, with 39.5 million individuals suffering from substance use disorders and 22 million experiencing problems specifically related to cocaine. The burden of addictive disorders is substantial: deaths from substance use disorders rose from 284,000 in 2007 to 352,000 in 2017, and drug use disorders rank among the leading mental health-related causes of disability-adjusted life years globally. Beyond mortality and morbidity, drug abuse exacts enormous societal costs through its associations with violence, economic productivity losses, and the strain on healthcare and criminal justice systems. The persistence of drug-seeking behavior despite mounting negative consequences has prompted extensive investigation into the neurobiological, psychological, and social mechanisms that maintain addiction. Historically, theoretical accounts have diverged considerably, ranging from neurobiological models emphasizing reward pathway dysregulation, to choice theories framing addiction as a disorder of decision-making, to the selfmedication hypothesis proposing that drug use functions to alleviate negative affective states. More integrative accounts have emerged in recent years, recognizing that addiction likely reflects the confluence of multiple interacting vulnerability factors operating at biological, psychological, and environmental levels.

This paper advances an integrative framework for understanding drug abuse that synthesizes evidence from four key domains: impulsivity and its relationship to emotion dysregulation; social cognition deficits, particularly in intentional harm recognition; reinforcement pathology as articulated through behavioral economic models; and transdiagnostic mechanisms including interoceptive and executive dysfunction. Drawing on recent theoretical developments, the author frames these vulnerabilities within a goal-directed regulatory model that conceptualizes addiction as emerging from maladaptive responses to discrepancies between current states and desired goals. Within this framework, drug abuse represents a failure of self-regulation wherein substances become the dominant, and often exclusive, strategy for managing aversive internal states and social demands.

The paper proceeds by first reviewing the epidemiology and developmental course of drug abuse, emphasizing the adolescent and young adult periods as critical windows of vulnerability. Th author then examines impulsivity as a multidimensional construct and present evidence for emotion dysregulation as a key mediator of the impulsivity-dependence relationship. Next, the author explores social cognition deficits, including recent findings on intentional harm recognition impairments among cocaine polydrug users. Following this, the author introduces the reinforcement pathology model and its application to polysubstance use patterns. The author then proposes an integrative transdiagnostic framework, synthesizing these disparate literatures and articulating pathways from vulnerability to chronic drug abuse. Finally, the author discusses clinical implications and future research directions.

Epidemiology and Developmental Course of Drug Abuse

The global prevalence of drug abuse varies considerably by substance and region. Cocaine use is particularly prevalent in South America, with Chile, Argentina, Uruguay, and Costa Rica reporting annual prevalence rates of 1.1% to 1.6%. Cannabis remains the most widely used illicit substance globally, with alcohol and tobacco also constituting major public health concerns. Importantly, polydrug use—the concurrent or sequential use of multiple substances—is increasingly recognized as the modal pattern of drug abuse rather than an exception. Among young adults, patterns of alcohol, tobacco, and cannabis co-use are particularly common, with polysubstance use associated with greater likelihood of problematic consumption and adverse health outcomes.

Adolescence and young adulthood represent critical developmental periods for drug abuse, onset and escalation. During this developmental window, several bio-psycho-social factors converge to heighten vulnerability: significant independence from guardians, changes in social roles, enhanced reward sensitivity, sensation-seeking, and the normative availability of substances in social contexts. Research on heroin addiction among adolescents has demonstrated that neurobiological alterations, including decreased serum brain-derived neurotrophic factors and increased dopamine levels, accompany cognitive deficiencies in inhibitory control. These neurobiological changes co-occur with sociodemographic risk factors, including father death, family conflict, having a family member with addiction, financial stress, and lower socioeconomic status.

The developmental trajectory of drug abuse involves characteristic progression from initiation to problematic use. Theories of substance use development posit that positive reinforcement—the euphoric, anxiolytic, or socially facilitating effects of substances—drives early use, but repeated cycles of intoxication and withdrawal progressively shift toward negative reinforcement processes. Across episodes of use and abstinence, negative reinforcement processes expand beyond relief of withdrawal-driven hedonic dysregulation to encompass mitigation of aversive affective states arising outside the withdrawal context. Longitudinal evidence supports this transition: negative reinforcement becomes an increasingly dominant predictor of use as dependence develops, whereas positive reinforcement alone predicts use among those without symptoms.

Research has consistently identified two broad pathways to drug abuse: internalizing and externalizing. Internalizing pathways involve negative affect, inhibition, and symptoms of anxiety and depression, with substance use purportedly functioning to reduce aversive affective states—the affective reinforcement hypothesis. However, a recent prospective co-twin control analysis found that the association between internalizing distress and substance use problems is primarily attributable to common genetic and shared environmental influences rather than causal effects. In contrast, externalizing behaviors—including impulsivity, disinhibition, sensation-seeking, and antisocial behavior—demonstrated consistent non-familial causal influences on alcohol and cannabis use problems from adolescence through young adulthood. This suggests that externalizing pathways may serve as unique determinants of drug abuse, with elevated externalizing increasing selection into peer environments that normalize and sustain heavy use.

Impulsivity and Emotion Dysregulation in Drug Abuse

Impulsivity is a multidimensional construct encompassing tendencies to react rapidly and without forethought to internal or external stimuli, with insufficient consideration of negative consequences. The Barratt Impulsiveness Scale, considered the gold standard assessment of trait impulsivity, identifies three dimensions: attentional impulsiveness (inability to focus attention and quick decision-making), motor impulsiveness (acting without thinking), and non-planning impulsiveness (inability to plan for present and future). Substance users consistently report higher levels of self-reported impulsivity compared to non-using controls. Elevated impulsivity scores are associated with greater number of cigarettes smoked, problematic alcohol use, significant escalation of problematic drug use, and higher risk of relapse and worse treatment outcomes. Experimental paradigms have corroborated these self-report findings, with drug users exhibiting steeper delay discounting—preference for smaller immediate rewards over larger delayed rewards—on behavioral tasks.

Emotion dysregulation encompasses maladaptive ways of responding to one’s emotions, including lack of emotional awareness, clarity, and acceptance; behavioral dyscontrol in the context of intense emotions; unwillingness to pursue meaningful activities during emotional distress; and inflexible use of adaptive emotion regulation strategies. Substance users report higher levels of emotion dysregulation compared to controls, with greater difficulties in concentrating and accomplishing tasks when experiencing negative emotions, accessing effective emotion regulation strategies, maintaining behavioral control during negative emotional states, and understanding experienced emotions.

Crucially, emotion dysregulation may mediate the relationship between impulsivity and severity of substance dependence. A mediation analysis involving treatment-seeking substance users found that emotion dysregulation mediated the association between attentional impulsivity, motor impulsivity, and nonplanning impulsivity and severity of substance dependence, with the direct effect of impulsivity on dependence severity becoming non-significant after accounting for emotion dysregulation. This suggests that among individuals with impulsive tendencies, difficulties in emotion regulation may exacerbate the severity of substance dependence, positioning emotion dysregulation as a key therapeutic target. The relationship between impulsivity and emotion dysregulation may reflect shared underlying neurobiological substrates. Both constructs implicate prefrontal cortex and amygdala circuitry, regions critical for emotion regulation, decision-making, risk-taking, and motor control. A vicious circle may operate in which impulsivity and emotion dysregulation mutually reinforce each other, with prioritization of affect regulation contributing to destructive patterns of failed impulse control.

Research on adolescent heroin addiction has identified specific neurobiological alterations that accompany cognitive deficiencies. Adolescents with heroin use disorder exhibited significantly decreased serum brain-derived neurotrophic factor and significantly increased dopamine levels compared to healthy controls. These neurobiological changes were associated with impaired inhibitory control, as measured by Stroop color word and colored number tests, with time interference scores significantly higher and interference scores significantly lower among heroin users. The impairment in inhibitory control among drug-abusing adolescents has profound implications for decisionmaking, impulse regulation, and vulnerability to continued drug abuse.

Social Cognition Deficits in Drug Abuse

Social cognition—the ability to understand and respond appropriately to social information—is critical for effective interpersonal functioning, empathy, and moral decision-making. Deficits in social cognition have been documented across various psychiatric populations and may be particularly relevant to drug abuse given the association between substance use and violence, interpersonal conflict, and social isolation. The likelihood of being involved in violent crimes increases by a factor of four among cocaine users, and exposure to violence is more than twice as high among cocaine users compared to the general population.

Intentional harm recognition—the ability to determine whether a harmful action performed by another person is deliberate or accidental—represents a critical social-cognitive capacity. This capability involves integrating complex emotional and cognitive processes and is moderated by individual psychological traits. Understanding the intentions of others is fundamental to empathy and moral decision-making; misinterpreting others’ choices can lead to miscommunication, arguments, and unpleasant interpersonal experiences. Impaired intentional harm recognition among drug users may contribute to heightened violence exposure and interpersonal deficits, potentially creating cascading social consequences that perpetuate drug abuse.

A recent high-density electroencephalography study examined intentional harm recognition in cocaine polydrug users compared to demographically and socioeconomically matched healthy controls. Participants completed the Intentional Inference Task, which assesses rapid intention inference regarding actions involving harm to others with different targets. Behaviorally, cocaine polydrug users exhibited slower reaction times than healthy controls, suggesting processing deficits in social-cognitive tasks. At the neural level, event-related potential analysis revealed late frontal differences in health controls when attributing intentional harm, while these differences were absent in cocaine users. This pattern suggests a shift in cocaine users toward emotional over-involvement and away from rational cognitive assessment of social information. The authors proposed that cocaine polydrug users may process social information differently, potentially engaging emotional processes while disengaging from rational evaluation of others’ intentions.

These findings are consistent with broader evidence of sociocognitive impairment among stimulant users. The absence of frontal ERP modulation in cocaine users during intentional harm recognition indicates that chronic stimulant use may disrupt the neural circuitry underlying theory of mind and social decisionmaking. Given that intention recognition involves early and late brain responses involving the amygdala and frontotemporal coupling, disrupted functioning in these circuits may have cascading effects on social behavior. The link between impaired intentional harm recognition and violence exposure is particularly concerning given the elevated rates of violence among drug users. While causal links between drug abuse and violence cannot be definitively ascertained, the evidence suggests that cocaine use may be directly linked to violent crime through disinhibition effects. However, socioeconomic status may also account for the association between drug abuse and violence, as the same factors underpinning exposure to violence and drug abuse among those of low socioeconomic status may also be related to other deficits in daily life functioning.

The bidirectional relationship between social-cognitive deficits and drug abuse warrants attention. People with substance use disorders exhibit deficits in socio-affective and cognitive function. These deficits may be the precipitant to or consequence of regular drug use. The effects of frequent drug use, such as blunted reward and general disinhibition, may increase the likelihood of using greater quantities and a larger variety of drugs. Lack of social support and adaptive coping strategies, along with easy access to drugs, is likely to promote and maintain drug abuse among individuals from lower socioeconomic strata. Lack of rewarding social encounters, along with insufficient social support, may impact initial and continued drug use. Continued use dynamically interacts with vulnerability factors, creating further social and functional impairments that may be potentiated by social stressors or socioeconomic status.

Reinforcement Pathology in Drug Abuse

Behavioral economics provides a theoretical framework for understanding drug abuse by integrating principles from psychology and microeconomics. The contextualized reinforcer pathology model articulates addictive behaviors through three core constructs. First, individuals with drug abuse histories exhibit persistently high valuation of drug reinforcers, meaning they are willing to expend greater effort and resources to obtain substances. Higher drug demand is associated with frequency, quantity, and severity of use. Second, these individuals demonstrate excessive preference for immediate reinforcers despite long-term negative outcomes, a phenomenon known as delay discounting. Steeper delay discounting is characteristic of drug users and predicts poorer treatment outcomes. Third, drug abuse is associated with a high ratio of reinforcement derived from substance use compared to substance-free activities, reflecting a constricted behavioral repertoire wherein substance-related activities come to dominate reinforcement while engagement in alternative reinforcers declines. All three constituents of the contextualized reinforcer pathology model are associated with clinically relevant aspects of drug abuse and treatment outcomes. Importantly, these factors are malleable, as shown in clinical studies, suggesting that intervening on these mechanisms may lead to enduring reductions in drug abuse.

Most prior research on reinforcer pathology has focused on users of only two substances, limiting understanding of the more complex polysubstance use patterns that characterize many drugabusing populations. A recent study examining young adults reporting alcohol only, alcohol with tobacco or cannabis, and alcohol with tobacco and cannabis use found that higher alcohol demand intensity and reinforcement from substance-related activities significantly predicted co-use of all three substances compared to alcohol-only use.

However, delay discounting and some alcohol demand indices were not associated with any substance use pattern. These findings suggest that polysubstance use may enhance reward from leisure and social activities rather than reflecting general deficits in delay discounting. Individuals with high reinforcement from substance-related activities or high drug demand should be delivered interventions promoting activities that are both reinforcing and serve as alternatives to drug use. The finding that delay discounting did not differentiate substance use patterns in this study is notable, as prior research has shown mixed findings for delay discounting across different substance use groups, potentially reflecting differences in task paradigms and population characteristics. The contextualized reinforcer pathology model has significant implications for understanding the development and maintenance of drug abuse. The constriction of alternative reinforcement means that as drug abuse progresses, individuals have fewer competing activities that provide reward, making drug use increasingly dominant. This is consistent with the goal-directed vulnerability framework’s emphasis on restricted behavioral repertoire as a key vulnerability factor.

An Integrative Transdiagnostic Framework

Recent theoretical developments have proposed a goaldirected vulnerability framework for understanding substance use disorders. This model conceptualizes motivated behavior as emerging from the detection and resolution of discrepancies between the current situation and an internal goal. Regulation occurs through three strategies: assimilation, which involves acting to align the situation with the goal; accommodation, which involves modifying or replacing the goal, so it no longer conflicts with the situation; and immunization, which involves reinterpreting the situation, so it no longer appears discrepant with the goal. In the context of drug abuse, individuals may disproportionately default to assimilation, using substances as the most immediate and effective means of reducing experienced discrepancies. This reliance on drug use as a “quick fix” illustrates how assimilation can become the dominant and maladaptive regulatory strategy.

The goal-directed model identifies five key vulnerabilities that converge to produce drug abuse. First, inflated discrepancy detection involves heightened sensitivity to the mismatch between situation and desired state, arising from social adversity, isolation, insecure attachment, psychiatric comorbidities, stress reactivity, and deficits in social cognition. These factors make individuals acutely aware of not fitting in or failing to meet standards. Additional factors such as trauma, stigma, and cultural pressures further magnify discrepancy detection. Second, heightened valuation of drug-related goals occurs when reward- and reliefdriven motives, comorbid anxiety and depression, polysubstance use, and impaired decision-making bias valuation toward drugrelated outcomes.

Social environments marked by peer pressure or dysfunction further amplify this bias. Beyond these factors, additional computational vulnerabilities contribute, including steeper temporal discounting, heightened aversion to uncertainty, and biased learning from drug-related experiences. Third, individuals with drug abuse histories exhibit maladaptive strategic preferences, disproportionately defaulting to assimilation rather than engaging in accommodation or immunization. Fourth, restricted behavioral repertoire emerges from cognitive and social-cognitive deficits, psychiatric comorbidities, and social adversity that constrain adaptive responses, channeling behavior toward drug abuse. Limited access to alternative rewards and reduced engagement in non-substance-related activities confer longitudinal risk of substance dependence.

Fifth, rigid outcome expectancies result from impaired cognitive flexibility, psychiatric comorbidities, stress, fatigue, and time pressure converging toward rigid expectancies about drug effects. Traumatic experiences such as emotional neglect early in life foster rigid patterns of thought and biased uncertainty valuation. At the basis of these vulnerabilities lie at least two transversal mechanisms: interoceptive dysfunction and executive dysfunction. Interoceptive dysfunction, with the insula as a hub, amplifies craving and stress signals, inflating discrepancies, heightening valuation, biasing strategies toward assimilation, and consolidating rigid expectancies. The insula’s role in representing internal bodily states means that dysfunction in this region may lead to heightened sensitivity to withdrawal-related aversive states and amplified craving responses to drug-related cues. This creates a self-perpetuating cycle wherein interoceptive signals drive drug-seeking behavior, which in turn further disrupts interoceptive processing.

Executive dysfunction involves impairments in cognitive control, working memory, and decision-making that impair the ability to regulate drug-seeking behavior. Deficits in executive function among drug users have been documented across multiple studies, with impairments in inhibitory control, cognitive flexibility, and planning. These deficits may both precede and result from chronic drug abuse, as substance-induced neuroadaptations further impair prefrontal cortical functioning. An additional integrative framework, the DREXI3 model, conceptualizes addiction as a chronic dysregulation of organism systems leading to internalizing or externalizing phenomena. This model proposes that emotions and behavior are responses to risk prediction, with individuals making choices and engaging in actions to manage potential risks and rewards to maintain homeostasis—a mechanism termed “predostatic” (predictive mechanism with homeostatic purpose).

The model identifies three main modes of the predostatic mind: Alarm Mode, activated by high and imminent risk prediction and associated with threat detection and defensive responses; Seek Mode, activated by long-term risk or reward prediction and associated with approach behavior and resource acquisition; and Balance Mode, a self-regulating state related to low-risk prediction, soothing, and calm. Addiction is conceptualized as persistent dysregulation of the Seek and Alarm Modes, which are constantly activated by reward and risk prediction respectively, hindering access to Balance Mode. Chronic drug use leads to neuroadaptations in brain reward circuitry that disrupt normal balance and regulation of reward processes, contributing to persistent drug-seeking despite negative consequences. The DREXI3 model proposes six dysregulation dimensions with basic emotional and behavioral symptoms: neurophysiological alterations, impulsivity, compulsion, cognitive impairment or psychosis, mood disturbance, and anxiety or anger. Integrating the evidence reviewed above, a comprehensive framework for understanding drug abuse must account for multiple interacting levels of vulnerability. At the neurobiological level, drug abuse involves dysregulation of reward circuitry, with neuroadaptations in dopamine systems, alterations in brain-derived neurotrophic factor signaling, and impaired prefrontal cortical function. These neurobiological changes affect both executive control and interoceptive processing, creating a neural substrate for continued drug-seeking. At the cognitive level, drug abuse is characterized by elevated impulsivity across multiple domains, impairments in executive function and inhibitory control, and deficits in social cognition including impaired intentional harm recognition.

These cognitive vulnerabilities may both predispose to drug abuse and be exacerbated by chronic substance use. At the emotional level, drug abuse involves emotion dysregulation, with substances functioning as primary and often exclusive strategies for managing aversive affective states. The relationship between impulsivity and dependence severity is mediated by emotion dysregulation, highlighting the critical role of affective processes in addiction. At the behavioral level, drug abuse reflects reinforcement pathology, with elevated valuation of drugrelated reinforcers, excessive delay discounting, and constricted engagement in substance-free activities.

Polysubstance use further enhances reinforcement from social and leisure activities, creating complex patterns of substancerelated reward. At the social and environmental level, drug abuse is shaped by socioeconomic status, peer influences, exposure to violence, social support deficits, and early adverse experiences including trauma and family conflict. These factors contribute to inflated discrepancy detection, restricted behavioral repertoire, and rigid outcome expectancies. This integrated framework suggests that drug abuse is best understood as a disorder of selfregulation that emerges from the confluence of vulnerabilities across multiple domains. The transition from initial drug use to chronic abuse reflects the progressive dominance of drug-related goals and strategies, the erosion of alternative reinforcers, and the deepening of neurocognitive and social impairments.

Clinical Implications and Future Directions

Given the finding that emotion dysregulation mediates the relationship between impulsivity and severity of substance dependence, interventions targeting emotion regulation may be particularly beneficial for drug-abusing individuals with impulsive tendencies. Mindfulness-based relapse prevention, acceptance and commitment therapy, and dialectical behavior therapy have shown promise in addressing emotion dysregulation in substanceusing populations. These approaches can help individuals develop alternative strategies for managing aversive emotional states, reducing reliance on substances as primary coping mechanisms. Additionally, pharmacological agents such as acamprosate may dampen stress reactivity and hyperkatifeia, potentially reducing discrepancy detection and craving. However, psychosocial interventions remain the cornerstone of treatment for many drugabusing populations, particularly given the multifaceted nature of addiction vulnerability.

The identification of social cognition deficits, including impaired intentional harm recognition among cocaine polydrug users, suggests the potential clinical benefits of interventions focused on socio-emotional regulation training. Given the link between drug abuse and violence exposure, interventions that improve social-cognitive abilities and interpersonal functioning may have cascading benefits for both drug abuse outcomes and violence prevention. The finding that frontal ERP differences were absent in cocaine users during intentional harm recognition suggests that neurocognitive remediation approaches targeting prefrontal function may be beneficial. Such approaches could include cognitive training exercises designed to enhance executive function and theory of mind processes.

The contextualized reinforcer pathology model suggests that interventions should promote engagement in substance-free activities that are both reinforcing and serve as alternatives to drug use. Individuals with high reinforcement from substance-related activities or high drug demand may particularly benefit from interventions that expand the behavioral repertoire and increase access to alternative reinforcers. This could involve behavioral activation approaches that systematically increase engagement in rewarding non-drug activities, contingency management that provides incentives for drug-free behavior, and community reinforcement approaches that build social and vocational skills. The finding that polysubstance use enhances reward from social, and leisure activities suggests that building alternative sources of reinforcement may be particularly important for individuals using multiple substances.

The identification of interoceptive dysfunction and executive dysfunction as transversal mechanisms underlying multiple vulnerabilities suggests that interventions targeting these processes may have broad benefits. Mindfulness-based interventions may improve interoceptive awareness and reduce reactivity to craving and stress signals. Cognitive remediation approaches may enhance executive function, working memory, and inhibitory control. Pharmacological interventions targeting insula-based circuits may also hold promise, though further research is needed. Several important directions for future research emerge from this integrative framework. Longitudinal studies tracking the development of social cognition deficits are needed to determine whether impairments in intentional harm recognition and other social-cognitive processes precede drug abuse or result from chronic exposure to substances.

Intervention studies targeting emotion dysregulation and impulsivity through randomized controlled trials are needed to evaluate whether interventions addressing emotion dysregulation reduce severity of substance dependence, particularly among individuals with high impulsivity. Neuroscientific investigations of reinforcement pathology using neuroimaging and neurophysiological methods are needed to elucidate the neural circuitry underlying drug demand, delay discounting, and alternative reinforcement. Translational research on polysubstance use is critical given that the majority of drug users use multiple substances, yet most research focuses on single substances. Developmental studies of vulnerability pathways from childhood adversity to adolescent drug abuse to chronic addiction are needed to identify critical windows for intervention. Finally, personalized treatment approaches are essential given the heterogeneity of drug abuse and the multifaceted nature of vulnerability, requiring research on matching interventions to individual profiles [1-59].

Conclusion

Drug abuse represents a complex, multifaceted disorder involving the interplay of neurobiological, cognitive, emotional, behavioral, and social vulnerabilities. The evidence reviewed in this paper supports an integrative framework wherein impulsivity and emotion dysregulation, social cognition deficits, and reinforcement pathology converge to produce and maintain addictive behaviors. These vulnerabilities operate through goal-directed regulatory processes, with drug abuse reflecting maladaptive strategies for managing discrepancies between current states and desired goals. The mediating role of emotion dysregulation in the impulsivity-dependence relationship suggests that interventions targeting emotion regulation may have cascading benefits for drug abuse outcomes.

The identification of impaired intentional harm recognition among cocaine users suggests that socio-emotional regulation training may be beneficial. The reinforcement pathology model highlights the importance of expanding the behavioral repertoire and promoting alternative reinforcers. Transdiagnostic mechanisms including interoceptive and executive dysfunction provide additional intervention targets. Future research should continue to integrate evidence across disciplines, addressing the multiple levels of vulnerability that characterize drug abuse. Such integrative approaches hold promises for developing more effective prevention and treatment interventions that address not only drug use itself but the underlying cognitive, emotional, and social processes that sustain addictive behavior. By moving beyond single-factor models to embrace the complexity of addiction, researchers and clinicians can develop more nuanced, personalized approaches to reducing the burden of drug abuse on individuals, families, and communities.

References

1. Juan P, Nicholas T, Daniela H, Alvaro R, Consuelo S, et al. (2025) Cocaine polydrug use and its impact on intentional harm recognition: a high-density EEG study. BMC Psychology 13(1): 917.
2. Zunera T, Muhammad R, Irfan S, Hafiz M, Mohammad Z (2025) Heroin Addiction is Associated with Cognitive Deficiency, Neurobiological Alterations and Socio-Demographic Factors in Adolescents. Psychological Reports.
3. Katherine T, Daniel J, William G, Matt M, Brian M (2026) A prospective co-twin control analysis of internalizing and externalizing pathways for alcohol, nicotine, and cannabis use problems from adolescence through adulthood. Psychological Medicine e227: 1-10.
4. Xavier N (2025) Bridging mechanistic heterogeneity and goal-directed regulation in substance use disorders: Commentary on Guerrin et al. Neuroscience & Biobehavioral Reviews 178: 106394
5. Angel G, Alba G, Roberto S, Gema A, Sara W, et al. (2025) Assessment of contextualized reinforcement pathology in a community sample of young adult substance users. Alcoholism: Clinical and Experimental Research 49(6): 1263-1272.
6. Giovanni M, Sara P, Ana V, Gabriele C, Marcantonio M (2026) The Mediating Role of Emotion Dysregulation in the Association Between Impulsivity and Severity of Substance Dependence. Clinical Psychology & Psychotherapy 33(2): e70250.
7. Bibiana B, Anne O, Melina N, Felipe O, Eduardo P (2024) Proposing an integrative, dynamic and transdiagnostic model for addictions: dysregulation phenomena of the three main modes of the predostatic mind. Frontiers in Psychiatry 14: 1298002.
8. Timothy I, Thomas W, Justin P, Melissa T, Daniel B (2024) Longitudinal examination of marijuana use and physical teen dating violence: Antisocial peers and impulsivity as mediators. Child Abuse & Neglect 156: 107016.
9. Rachel L, Will L, Kat P, Amelia B, Katie T, et al. (2024) Persistent increased severity of cannabis use disorder symptoms in adolescents compared to adults: a one-year longitudinal study. European Archives of Psychiatry and Clinical Neuroscience 275(2):397-406.
10. Volkow ND, Blanco C (2023) substance use disorders: A comprehensive update on prevalence, etiology, and treatment. Annual Review of Medicine.
11. Koob GF, Volkow ND (2016) Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry 3(8): 760-773.
12. Bickel WK, Matthew W, Mikhail N, James M, James G (2014) The behavioral economics of substance use disorders: Reinforcement pathologies and their repair. Annual Review of Clinical Psychology 10: 641-677.
13. Gratz KL, Roemer L (2004) Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the Difficulties in Emotion Regulation Scale. Journal of Psychopathology and Behavioral Assessment 26(1): 41-54.
14. Stanford MS (2009) Fifty years of the Barratt Impulsiveness Scale: An update and review. Personality and Individual Differences 47(5): 385-395.
15. Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt Impulsiveness Scale. Journal of Clinical Psychology, 51(6): 768-774.
16. Acuff SF (2023) The contextualized reinforcer pathology model: A framework for understanding substance use disorders. Psychology of Addictive Behaviors.
17. Krueger RF, Brian M, Christopher J, Scott R, William G, et al. (2002) Etiologic connections among substance dependence, antisocial behavior, and personality: Modeling the externalizing spectrum. Journal of Abnormal Psychology 111(3): 411-424.
18. Khantzian EJ (1997) The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry 4(5): 231-244.
19. West R (2006) Theory of Addiction. Blackwell Publishing.
20. Cannon WB (1932) The Wisdom of the Body. W.W. Norton & Company.
21. (2013) American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fifth Edition.
22. (2019) World Health Organization International Statistical Classification of Diseases and Related Health Problems (11^th edn).
23. (2023) Substance Abuse and Mental Health Services Administration Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health.
24. (2022) European Monitoring Centre for Drugs and Drug Addiction European Drug Report 2022: Trends and Developments.
25. (2022) United Nations Office on Drugs and Crime World Drug Report 2022.
26. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392(10159): 1789-1858.
27. Foster KT, Hicks BM, Iacono WG, McGue M (2014) Gender differences in the structure of psychopathology in a sample of young adults. Journal of Abnormal Psychology 123(2): 298-311.
28. Colder CR, Read JP, Lengua LJ, Hawk LW, Wieczorek WF (2020) Internalizing and externalizing pathways to alcohol use and problems. Development and Psychopathology 32(2): 431-444.
29. Boden JM, Fergusson DM (2011) Alcohol and depression. Addiction 106(5): 906-914.
30. Crum RM (2013) A prospective assessment of reports of drinking to cope with negative affect and the risk of alcohol use disorders. Addiction 108(1): 50-58.
31. Amlung M, MacKillop J, Lana V, John A, Iris B, et al. (2017). Steep delay discounting and addictive behavior: A meta-analysis of continuous associations. Addiction 112(1): 51-62.
32. Murphy JG (2019) Behavioral economic approaches to reducing substance use: A review and synthesis. Psychology of Addictive Behaviors 33(3): 219-235.
33. Naudé GP (2022) Delay discounting and substance use patterns in young adults. Drug and Alcohol Dependence 230: 109177.
34. Nieto J (2022) Behavioral economic profiles of polysubstance use in young adults. Experimental and Clinical Psychopharmacology 30(4): 451-462.
35. Moody LN (2016) Delay discounting and polysubstance use in a community sample. Psychology of Addictive Behaviors, 30(5): 545-555.
36. Minhas M (2020) Alcohol demand and delay discounting in alcohol and cannabis co-users. Alcoholism: Clinical and Experimental Research 44(6): 1255-1265.
37. Businelle MS (2010) The relation between delay discounting and alcohol dependence. Experimental and Clinical Psychopharmacology 18(2): 135-144.
38. Loree AM (2015) Impulsivity and substance use disorders: A review of the literature. Current Psychiatry Reports 17(11): 87.
39. DeVito EE (2020) Impulsivity and substance use disorders: A meta-analytic review. Drug and Alcohol Dependence 207:
40. Stellern J (2023) Emotion dysregulation and substance use severity: A systematic review. Clinical Psychology Review 99: 102237.
41. Weiss NH (2022) Emotion dysregulation and substance use: A meta-analytic review. Journal of Consulting and Clinical Psychology 90(5): 413-427.
42. Garofalo C, Velotti P (2015) The relationship between impulsivity and emotion dysregulation: A review of the literature. Clinical Neuropsychiatry 12(3): 62-71.
43. Schreiber LR (2012) The role of impulsivity and emotion dysregulation in substance use disorders. Journal of Substance Abuse Treatment 43(4): 421-429.
44. Selby EA (2008) The role of emotion dysregulation in the relationship between impulsivity and psychopathology. Journal of Abnormal Psychology 117(2): 319-330.
45. Bechara A, Damasio H, Damasio AR, (2000) Emotion, decision making and the orbitofrontal cortex. Cerebral Cortex 10(3): 295-307.
46. Ochsner KN, Gross JJ (2005) The cognitive control of emotion. Trends in Cognitive Sciences 9(5): 242-249.
47. Sinha R (2008) Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences 1141: 105-130.
48. Baker TB, Megan E, Danielle E, Matthew R, Michael C (2004) Addiction motivation reformulated: An affective processing model of negative reinforcement. Psychological Review 111(1): 33-51.
49. Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annual Review of Psychology 59: 29-53.
50. Cicchetti D, Rogosch FA (1996) Equifinality and multifinality in developmental psychopathology. Development and Psychopathology 8(4): 597-600.
51. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236(4800): 410-416.
52. Iacono WG (1999) Behavioral disinhibition and the development of substance use disorders. Development and Psychopathology 11(4): 869-900.
53. Volkow ND, Blanco C (2023) The changing landscape of substance use disorders. American Journal of Psychiatry 180(1): 12-14.
54. Friedmann PD, Schwartz RP (2012) Just call it "treatment". Addiction Science & Clinical Practice 7(1): 10.
55. Bickel WK (2023) The malleability of reinforcement pathology: A review of behavioral interventions. Journal of the Experimental Analysis of Behavior 119(1): 132-151.
56. García Pérez Á (2022) Environmental reward and substance use: A review of the contextualized reinforcer pathology model. Current Addiction Reports 9(3): 187-198.
57. González Roz A (2019) Delay discounting and substance use: A systematic review and meta-analysis. Addiction 114(5): 801-812.
58. Aonso Diego G (2021) Polysubstance use and reinforcement pathology: A review. Journal of Behavioral Addictions 10(3): 482-496.
59. Yurasek AM (2017) Polysubstance use among young adults: A review of the literature. Current Addiction Reports 4(4): 413-424.